Tidal Investments LLC Has $47.48 Million Holdings in Pfizer Inc. $PFE

Tidal Investments LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,971,885 shares of the biopharmaceutical company’s stock after buying an additional 46,450 shares during the quarter. Tidal Investments LLC’s holdings in Pfizer were worth $47,483,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PFE. Brighton Jones LLC raised its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. United Bank grew its position in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. increased its holdings in Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC boosted its stake in Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after purchasing an additional 31,896 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PFE. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, September 5th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Finally, UBS Group reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Stock Up 0.1%

NYSE:PFE opened at $27.82 on Thursday. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $29.21. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $158.58 billion, a P/E ratio of 36.61, a P/E/G ratio of 1.87 and a beta of 0.34. The stock’s fifty day simple moving average is $26.21 and its 200-day simple moving average is $26.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company posted $0.78 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s latest quarterly results exceeded expectations, with adjusted earnings of $0.77 per share versus the $0.68 consensus and revenue of $15.03 billion versus estimates of $14.40 billion. The results helped revive the stock after a prolonged downturn and reinforced management’s full-year 2026 EPS guidance of $2.80-$3.00. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Analysts point to Pfizer’s non-COVID portfolio, oncology pipeline and cost-cutting initiatives as potential growth and margin supports. These factors could help offset falling COVID product sales and extend the company’s recovery. Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
• Neutral Sentiment: Pfizer will present at the Morgan Stanley Global Healthcare Conference on September 14. Chief Executive Albert Bourla’s comments could provide updates on the pipeline, capital allocation and the company’s strategy for managing patent losses. Pfizer Invites Public to Listen to Webcast
• Neutral Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension product. The transaction may generate cash and streamline Pfizer’s portfolio, but its financial impact appears limited relative to Pfizer’s roughly $159 billion market value. Novartis India Acquires Pfizer Brands
• Negative Sentiment: Jim Cramer selected Johnson & Johnson over Pfizer among healthcare stocks, a high-profile preference that may weigh on Pfizer’s relative appeal. Another comparison favored AbbVie as a stronger dividend-growth investment, despite Pfizer’s roughly 6% yield. Jim Cramer Picks J&J Over Pfizer

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.